

---

## Amygdala Neurosciences Acquires GS-6637 From Gilead Sciences

FEBRUARY 24, 2017

On February 16, 2017, Amygdala Neurosciences Inc., a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders, announced that it entered into an agreement with Gilead Sciences, Inc. for the acquisition of GS-6637. GS-6637 is a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions based on a mechanism of action that prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine.

WilmerHale is serving as legal counsel to Gilead on this transaction, with [Eric Hwang](#) leading the team that includes [John Lee](#) and [Cindy Moon](#).

Read the full [press release](#).